Erythropoietin improves quality of life
- 1 August 2002
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (8) , 459-460
- https://doi.org/10.1016/s1470-2045(02)00827-6
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?The Lancet Oncology, 2002
- Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2001
- Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly DosingJournal of Clinical Oncology, 2001
- Epoetin alfa overcomes much of the QOL deficit seen in anaemic cancer patientsEuropean Journal Of Cancer, 2001
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.Journal of Clinical Oncology, 1998
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997